![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
AstraZeneca |
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00506051 |
The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.
Condition | Intervention | Phase |
Carcinoma Non-Small Cell Lung Lung Cancer |
Drug: ZD6474 (vandetanib) Drug: pemetrexed |
Phase I |
MedlinePlus related topics: | Cancer Lung Cancer |
ChemIDplus related topics: | Pemetrexed disodium Pemetrexed Vandetanib |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of Prior Chemotherapy. |
Enrollment: | 21 |
Study Start Date: | July 2005 |
Estimated Study Completion Date: | March 2008 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
AstraZeneca Clinical Trial Information - Outside US 
![]()   |
Study ID Numbers: | D4200C00041 |
First Received: | July 3, 2007 |
Last Updated: | June 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00506051 |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration; Belgium: Directorate general for the protection of Public health: Medicines; Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|
|
![]() |